Flt-1 and Eng, as well as their soluble forms, have been demonstrated to reduce the bioavailability of the proangiogenic markers vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), thereby promoting vasoconstriction, endothelial dysfunction and PE [66,69,74]. The gene discussed is PGF; the disease is endothelial dysfunction.